Physician profile
Massimo Giusti
NPI 1720011398
$2,114.04
in general payments reported to CMS, 2019-2025
23 companies · $80.44 in 2025
The $80.44 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $266 · 2021: $301 · 2022: $444 · 2023: $387 · 2024: $144 · 2025: $80.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.30 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $272.92 | 2019-2023 | |
| Amgen INC. | $249.73 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $244.47 | 2019-2023 | |
| Boston Scientific Corporation | $192.31 | 2020-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $159.84 | 2019-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.08 | 2019-2022 | |
| Astellas Pharma US INC | $129.45 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $127.63 | 2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $81.02 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $79.37 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $62.63 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $59.07 | 2019 | |
| Philips North America LLC | $52.21 | 2023 | |
| Merck Sharp & Dohme LLC | $48.55 | 2021-2022 | |
| Heartflow, INC. | $45.88 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $35.07 | 2020-2024 | Rybelsus, Ozempic |
| Lundbeck LLC | $27.90 | 2019-2020 | |
| Atricure, INC. | $20.26 | 2021 | |
| Cvrx, INC. | $18.92 | 2024 | Barostim Neo System |
| Irhythm Technologies, INC. | $17.79 | 2023 | Zio Xt Patch |
| Abiomed | $15.68 | 2025 | |
| Gilead Sciences, INC. | $13.88 | 2019 | |
| Medtronic Vascular, INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massimo Giusti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.